A nasal spray that delivers a peptide to treat depression holds promise as a potential alternative therapeutic approach, research shows. This peptide treatment interferes with the binding of two dopamine receptors -- the D1 and D2 receptor complex. The research team had found that this binding was higher in the brains of people with major depression. Disrupting the binding led to the anti-depressant effects.